Which combined oral contraceptive formulation would be appropriate for a patient with circulatory disease due to cardiovascular risk, requiring a reduced estrogen dose?

Unlock all features

Unlock your full potential with Examzify Plus. Access the complete question bank, personalized progress tracking, and an ad-free experience.

Full question bankExam simulationsFlashcards

From $24.99Unlock all

Study for the Foundation Year Pharmacy – Clinical Practice Test. Prepare with detailed questions, step-by-step explanations, and test format insights. Enhance your readiness and confidence!

Multiple Choice

Which combined oral contraceptive formulation would be appropriate for a patient with circulatory disease due to cardiovascular risk, requiring a reduced estrogen dose?

Lowering the estrogen dose reduces the risk of thromboembolism in patients with circulatory disease. Among the options, the formulation with ethinylestradiol at 20 mcg provides contraception with the smallest estrogen exposure, while still supplying effective progestin activity with gestodene. The other combined options use higher estrogen doses (30 mcg or 50 mcg), which would increase cardiovascular risk, and a progestin-only option isn’t a combined oral contraceptive at all. So the lowest-estrogen, still-combined option is the best choice for reduced estrogen exposure in this context.

Which combined oral contraceptive formulation would be appropriate for a patient with circulatory disease due to cardiovascular risk, requiring a reduced estrogen dose?

Study for the Foundation Year Pharmacy – Clinical Practice Test. Prepare with detailed questions, step-by-step explanations, and test format insights. Enhance your readiness and confidence!

Which combined oral contraceptive formulation would be appropriate for a patient with circulatory disease due to cardiovascular risk, requiring a reduced estrogen dose?

Get the latest from Examzify